Dan Zhao is an Oncology physician affiliated with Texas A&M University System. OpenAlex indexes 28 publications with 655 citations (h-index 11); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1515 Holcombe Blvd
Houston, TX 770304000
Telephone
713-792-6161Provider last certified this registry record 2 Apr 2021.
Clinical trials
- Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
Sponsor: M.D. Anderson Cancer Center
- An Effectiveness-implementation Hybrid Study of Social Prescribing in a Singapore Community Hospital Setting
Sponsor: Bright Vision Hospital
- Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus
Sponsor: Hebei Medical University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ipsen Biopharmaceuticals, IncProgram year20252 payments
- Octapharma USA, Inc.Program year20251 payment
- TriSalus Life Sciences, Inc.Program year20242 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
55%Serotonin-3 Receptor Antagonist29.1%Ondansetron Hcl100%Part D≥29 patientsAntidiarrheal microorganisms13.2%Creon100%Part D≥15 patients+ 1 more class in this area
Nervous system
45%Phenothiazine28.5%Prochlorperazine Maleate100%Part D≥26 patientsAtypical Antipsychotic9.3%Olanzapine100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Serum cytokine profile of neonatal broiler chickens infected with Salmonella Typhimurium
Frontiers in Physiology
2024 - The complete mitogenome of <i>Paratanakia chii</i> (Cypriniformes; Cyprinidae)
Mitochondrial DNA Part B
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”